Upstream Bio Reports $33.7 Million Net Loss in Q3 2025, Increased R&D Expenses

Upstream Bio, Inc. reported significant financial results for the third quarter of 2025, revealing a net loss of $33.7 million, compared to a net loss of $16.0 million for the same period in 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $101.0 million, a substantial increase from the $41.6 million loss reported in the prior year. The increase in losses is primarily attributed to heightened research and development expenses, which surged to $96.6 million for the nine-month period, up from $41.2 million in 2024. The company's collaboration revenue also saw a modest increase, reaching $2.2 million for the nine months ended September 30, 2025, compared to $1.8 million in the same period last year.

The company's total operating expenses for the third quarter of 2025 amounted to $38.5 million, significantly higher than the $19.5 million reported in the same quarter of 2024. This increase was driven by a $17.5 million rise in research and development costs, reflecting ongoing clinical trials for its lead product, verekitug, which is being developed for severe respiratory disorders. General and administrative expenses also rose to $5.5 million from $4.1 million year-over-year, largely due to increased personnel costs and professional fees.

In terms of operational metrics, Upstream Bio's cash, cash equivalents, and short-term investments totaled $372.4 million as of September 30, 2025, a decrease from $479.2 million at the end of 2024. The company’s accumulated deficit reached $291.8 million, indicating the financial challenges it faces as it continues to invest heavily in its research and development efforts. The company has not yet generated revenue from product sales and does not anticipate doing so until it secures regulatory approval for verekitug.

Strategically, Upstream Bio has made significant advancements in its clinical programs, including the completion of enrollment in its Phase 2 trial for severe asthma and the initiation of a Phase 2 trial for chronic obstructive pulmonary disease (COPD). The company reported positive top-line results for its chronic rhinosinusitis with nasal polyps (CRSwNP) trial in September 2025. Upstream Bio's management remains focused on maximizing the potential of verekitug, which targets the Thymic Stromal Lymphopoietin receptor, a key driver of inflammatory responses.

Looking ahead, Upstream Bio anticipates continued operating losses as it progresses through its clinical trials and seeks regulatory approvals. The company expects that its existing cash reserves will be sufficient to fund operations through at least 2027, but it acknowledges the need for additional financing to support its growth strategy. The management's outlook emphasizes the importance of successful clinical outcomes and regulatory approvals in achieving future profitability.